Mapping the mutational landscape for streptokinase binding to plasminogen
Journal of Thrombosis and Haemostasis · 2026
DOI: 10.1016/j.jtha.2026.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Srishti Baid und 5 weiteren Autor:innen. Beteiligte Einrichtung: Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Streptokinase, Plasminogen, Mutation, Streptococcus pyogenes. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, American Heart Association Inc, National Heart Lung and Blood Institute.
Abstract (Originalsprache)
BACKGROUND: Group A Streptococcus (GAS) expresses streptokinase (SK), a critical virulence factor that nonenzymatically activates the host's plasminogen (PLG) to an active form (PLGSK) via a conformational change. PLGSK then activates PLG to plasmin, resulting in fibrinolysis and facilitating bacterial dissemination. As a potent thrombolytic, SK has been used as a therapeutic agent. OBJECTIVES: GAS SK is highly specific for human PLG, and sequence variation among SKs from different GAS strains has been linked to differences in PLG binding and disease severity. The contributions of individual amino acids to these differences remain poorly understood. METHODS: We used phage display and deep mutational scanning to map how amino acid substitutions in SK from Group C Streptococcus (GCS), which shares high sequence homology with GAS, affect its ability to bind human PLG. RESULTS: We demonstrate that SK, expressed as a fusion protein with the p3 coat protein of the M13 filamentous phage, retains its ability to bind human PLG. Deep mutational scanning mapped 71% of all possible single amino acid substitutions within SK, identifying specific regions where substitutions are likely to increase or decrease its affinity for PLG. CONCLUSION: Our findings suggest a complex protein-protein interaction in which long-range protein dynamics influence the conformational activation of PLG to PLGSK. These data lay the foundation for linking SK variation across GCS strains to differences in virulence, mapping the determinants of GCS SK's human specificity, and potentially contributing to the development of improved therapeutics for heart attack and stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA.
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA; Department of Ecology and Evolutionary Biology, University of Michigan, Ann Arbor, Michigan, USA.
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Human Genetics, University of Michigan, Ann Arb…
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: hayneslm@umich.edu.
Förderung
- NHLBI NIH HHS
- American Heart Association Inc
- National Heart Lung and Blood Institute
- National Institutes of Health
- American Society for Horticultural Science
- American Society of Hematology Inc
Zitieren
APA
Baid, S., Holding, M. L., Laurin, T., Siemieniak, D., Ginsburg, D., & Haynes, L. M. (2026). Mapping the mutational landscape for streptokinase binding to plasminogen. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.09.003
Vancouver
Baid S, Holding ML, Laurin T, Siemieniak D, Ginsburg D, Haynes LM. Mapping the mutational landscape for streptokinase binding to plasminogen. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.09.003
BibTeX
@article{Baid2026,
author = {Baid, Srishti and Holding, Matthew L and Laurin, Taylor and Siemieniak, David and Ginsburg, David and Haynes, Laura M},
title = {Mapping the mutational landscape for streptokinase binding to plasminogen},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
doi = {10.1016/j.jtha.2026.09.003}
}
EUVIMED